nogalamycin and Carcinoma--Squamous-Cell

nogalamycin has been researched along with Carcinoma--Squamous-Cell* in 1 studies

Trials

1 trial(s) available for nogalamycin and Carcinoma--Squamous-Cell

ArticleYear
Phase II evaluation of menogaril in patients with advanced cervical carcinoma. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
    Investigational new drugs, 1991, Volume: 9, Issue:4

    Fourteen patients with advanced/recurrent squamous cell carcinoma of the uterine cervix received menogaril, 200 mg/m2 by one hour intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was less than two months and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis occurred at the infusion site in 43% of patients. Menogaril as administered in this protocol is ineffective in treating previously irradiated advanced/recurrent squamous cell carcinoma of the uterine cervix and warrants no further investigation in this disease at the dosage and administration schedule used in this protocol.

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Menogaril; Middle Aged; Neoplasm Recurrence, Local; Nogalamycin; Uterine Cervical Neoplasms

1991